USE OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF ULCERATIVE COLITIS IN DIFFERENT DOSAGE MODES
https://doi.org/10.21518/2079-701X-2017-15-44-50
Abstract
Preparations of 5-ASA are the first line treatment of ulcerative colitis (UC). Today, in the market of drugs 5-ASA available for the treatment of UC, there are many dosage forms, varying in the coating, method of delivery of active substance and dosing regimens of the drug. The aim of this review is to compare these dosage forms by the main parameters: efficiency, safety and adherence to treatment.
About the Authors
M. V. Shapina
State scientific center of Coloproctology them. A. N. Redheads Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
I. L. Khalif
State scientific center of Coloproctology them. A. N. Redheads Ministry of Health of Russia
Russian Federation
Russian Federation
MD, Prof
References
1. Svartz N. Salazopyrin, a new sulfanilamide preparation. A. Therapeutic Results in Rheumatic Polyarthritis. B. Therapeutic Results in Ulcerative Colitis. C. Toxic Manifestations in Treatment with Sulfanilamide Preparations. Acta Med. Scand., 2009 Apr, 110(6): 577–598.
2. Peppercorn MA and Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J. Pharmacol. Exp. Ther., 1972 Jun, 181(3): 555–62.
3. Azad Khan AK, Piris J, and Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet (London, England), 1977 Oct, 2(8044): 892–5.
4. Klotz U, Maier K, Fischer C, and Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn’s disease. N. Engl. J. Med., 1980 Dec, 303(26): 1499–502,
5. van Hees PA, Bakker JH, and van Tongeren JH. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut, 1980 Jul, 21(7): 632–5.
6. Schröder H and Campbell DES. Absorption, meta bolism, and excretion of salicylazosulfapyridine in man. Clin. Pharmacol. Ther., 1972 Jul, 13(4): 539–551.
7. Haagen O Nielsen and Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br. J. Clin. Pharmacol., 1983 Dec, 16(6): 738–40.
8. Myers B, Evans DN, Rhodes J, Evans BK, Hughes BR, Lee MG, Richens A, and Richards D. Metabo lism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut, 1987 Feb, 28(2): 196–200.
9. Truelove SC and Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br. Med. J., 1955 Oct, 2(4947): 1041–8.
10. Truelove SC and Witts LJ. Cortisone and corticotrophin in ulcerative colitis. Br. Med. J., 1959, 1(5119): 387–394.
11. Misiewica JJ, Lennard-Jones JE, Connell AM. Controlled trial of sulfasalazine in maintenance therapy for ulcerative colitis. Lancet, 1965, 1: 185–8.
12. Sutherland L, May G, and Shaffer E. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med, 1993, 118, 540–9.
13. Nielsen OH. Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand. J. Gastroenterol., 1982 Apr, 17(3): 389–93.
14. D’Incà R. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis. World J. Gastroenterol., 2013, 19(34): 5665.
15. Das KM, Eastwood MA, McManus JPA, and Sircus W. Adverse Reactions during Salicy la-zosulfapyridine Therapy and the Relation with Drug Metabolism and Acetylator Phenotype. N. Engl. J. Med., 1973 Sep, 289(10): 491–495.
16. Sutherland LR and MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulce rative colitis. In Cochrane Database of Systema tic Reviews. Ed. Chichester, UK: John Wiley & Sons, Ltd, 2006.
17. Sutherland LR, Roth DE, and Beck PL. Alternatives to Sulfasalazine: A Meta-analysis of 5-ASA in the Treatment of Ulcerative Colitis. Inflamm. Bowel Dis., 1997, 3(2): 65–78.
18. Feagan BG and MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. In Cochrane Database of Systematic Reviews. Ed. Chichester, UK: John Wiley & Sons, Ltd, 2012.
19. Hardy JG, Healey JNC, and Reynolds JR. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther., 2007 Mar, 1(4): 273–280.
20. Dew MJ, Harries AD, Evans N, Evans BK, and Rhodes J. Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. Br. Med. J. (Clin. Res. Ed)., 1983, 287(6384): 23–4.
21. Князев О.В., Беляков Н.И., Каграманова А.В., Фадеева Н.А. Эффективность терапии язвенного колита средней степени тяжести месалазином ММХ. Терапия, 2017, 1(11).
22. Rasmussen SN, Bondesen S, Hvidberg EF, Hansen SH, Binder V, Halskov S, and Flachs H. 5-amino-salicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology, 1982 Nov, 83(5): 1062–70.
23. Данные инструкции по медицинскому применению препарата Пентаса гранулы, пролонгированного действия для приема внутрь: http://grls.rosminzdrav.ru.
24. Данные инструкции по медицинскому приме-нению препарата Пентаса таблетки, пролонгированного действия: http://grls.rosminzdrav.ru.
25. Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F, and European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Manage ment of Ulcerative Colitis. Part 2: Current Manage ment. J. Crohns. Colitis, 2017 Jul, 11(7): 769–784.
26. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, and Joseph R. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut, 2008, 57(7): 893–902.
27. Maier K, Frühmorgen P, Bode JC, Heller T, von Gaisberg U, and Klotz U. Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid. Dtsch. Med. Wochenschr., 1985 Mar, 110(10): 363–8.
28. Brunner M, Assandri R, Kletter K, Tschurlovits M, Corrado ME, Villa R, Eichler HG, and Müller M. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment. Pharmacol. Ther., 2003 Feb, 17(3): 395–402.
29. Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л. и др. Клинические рекомендации Российской Гастроэнтерологической Ассоциации и Ассоциации Колопроктологов России по диагностике и лечению язвенного колита. Колопроктология, 2017, 1(59).
30. Данные инструкции по медицинскому применению препарата Мезавант таблетки пролонгированного действия, покрытые кишечнорастворимой оболочкой: http://grls.rosminzdrav.ru.
31. Kruis W, Kiudelis G, Racz I, Gorelov IA, Pokrotnieks J, Horynski M, Batovsky M, Kykal J, Boehm S, Grein wald R, and Mueller R. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, rando mised, non-inferiority trial. Gut, 2009, 58(2): 233–240.
32. Flouri B, Hagge H, Tucat G, Maetz D, Hbuterne X, Kuyvenhoven JP, Tan TG, Pierik MJ, Masclee, O Dewit AAM, Probert CS, and Aoucheta D. Randomised clinical trial: Once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment. Pharmacol. Ther., 2013, 37(8): 767–775.
33. Kane S, Huo D, and Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin. Gastroenterol. Hepatol., 2003 May, 1(3): 170–3.
34. Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, and Kane S. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroentero-logy, 2010 Apr, 138(4): 1286–96, 1296–3.
35. D’Haens G, Sandborn WJ, Barrett K, Hodgson I, and Streck P. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis. Am. J. Gastroenterol., 2012 Jul, 107(7): 1064–77.
36. Kane S, Holderman W, Jacques P, and Miodek T. Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial. Patient Prefer. Adherence, 2008 Feb, 2: 253–8.
37. Bokemeyer B, Hommes D, Gill I, Broberg P, and Dignass A. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. J. Crohns. Colitis, 2012 May, 6(4): 476–82.
38. Prantera C, Kohn A, Campieri M, Caprilli R, Cottone M, Pallone F, Savarino V, Sturniolo GC, Vecchi M, Ardia A, and Bellinvia S. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX® with Asacol®. Aliment. Pharmacol. Ther., 2009 Nov, 30(9): 908–918.
39. Hawthorne AB, Stenson R, Gillespie D, Swarbrick ET, Dhar A, Kapur KC, Hood K, and Probert CSJ. One-year investigator-blind rand-omized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflamm. Bowel Dis., 2012 Oct, 18(10): 1885–93.
40. Kruis W, Jonaitis L, Pokrotnieks J, Mikhailova TL, Horyn ski M, Bátovský M, Lozynsky YS, Zakharash Y, Rácz I, Kull K, Vcev A, Faszczyk M, Dilger K, Grein wald R, and Mueller R. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative co li-tis. Aliment. Pharmacol. Ther., 2011 Feb, 33(3): 313–322.
41. Watanabe M, Hanai H, Nishino H, Yokoyama T, Terada T, and Suzuki Y. Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. Inflamm. Bowel Dis., 2013 Jul, 19(8): 1681–90.
42. Kane SV, Cohen RD, Aikens JE, and Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am.
43. J. Gastroenterol., 2001 Oct, 96(10): 2929–33.
44. Ediger JP, Walker JR, Graff L, Lix L, Clara I, Raw-sthorne P, Rogala L, Miller N, McPhail C, Deering K, and Bernstein CN. Predictors of medication adherence in inflammatory bowel disease. Am. J. Gastroenterol., 2007 Jul, 102(7): 1417–26.
45. Loftus EV. A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies. Inflamm. Bowel Dis., 2006 Dec, 12(12): 1107–13.
46. Белоусова Е.А., Никитина Н.В., Цодикова О.М. Лечение язвенного колита легкого и среднетяжелого течения. Фарматека. 2, 2013.
47. Lachaine J. et al. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. BMC Gastroenterology. 2013. 13.
Review
For citations:
Shapina MV, Khalif IL. USE OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF ULCERATIVE COLITIS IN DIFFERENT DOSAGE MODES. Meditsinskiy sovet = Medical Council. 2017;(15):44-50. (In Russ.) https://doi.org/10.21518/2079-701X-2017-15-44-50
Views:
3787
Email this article 